Titre :

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Auteur(s) :

Tam, C. S. [Auteur]
Monash University [Melbourne]
Kapoor, P. [Auteur]
Mayo Clinic [Rochester]
Castillo, J. J. [Auteur]
Dana-Farber Cancer Institute [Boston]
Buske, C. [Auteur]
Universitätsklinikum Ulm - University Hospital of Ulm
Ansell, S. M. [Auteur]
Mayo Clinic [Rochester]
Branagan, A. R. [Auteur]
Massachusetts General Hospital [Boston]
Kimby, E. [Auteur]
Karolinska Institutet [Stockholm]
Li, Y. [Auteur]
Baylor College of Medicine [BCM]
Palomba, M. L. [Auteur]
Memorial Sloan Kettering Cancer Center [MSKCC]
Qiu, L. [Auteur]
China Academy of Chinese Medical Sciences
Shadman, M. [Auteur]
University of Washington [Seattle]
Abeykoon, J. P. [Auteur]
Mayo Clinic [Rochester]
Sarosiek, S. [Auteur]
Dana-Farber Cancer Institute [Boston]
Vos, J. [Auteur]
University of Amsterdam [Amsterdam] = Universiteit van Amsterdam [UvA]
Yi, S. [Auteur]
Tianjin University [TJU]
China Academy of Chinese Medical Sciences
Stephens, D. [Auteur]
University of Utah
Roos-Weil, D. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Roccaro, A. M. [Auteur]
Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia]
Morel, Pierre [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Université de Picardie Jules Verne [UPJV]
Munshi, N. C. [Auteur]
Universitätsklinikum Ulm - University Hospital of Ulm
Anderson, K. C. [Auteur]
Universitätsklinikum Ulm - University Hospital of Ulm
San-Miguel, J. [Auteur]
Clínica Universidad de Navarra [Pamplona]
Garcia-Sanz, R. [Auteur]
Universidad de Salamanca [España] = University of Salamanca [Spain]
Dimopoulos, M. A. [Auteur]
National and Kapodistrian University of Athens [NKUA]
Treon, S. P. [Auteur]
Universitätsklinikum Ulm - University Hospital of Ulm
Kersten, M. J. [Auteur]
Tianjin University [TJU]

Titre de la revue :

Semin Hematol

Nom court de la revue :

Semin Hematol

Date de publication :

2023-04-29

ISSN :

1532-8686

Mot(s)-clé(s) en anglais :

IgM lymphoplasmacytic lymphoma
Waldenstrom macroglobulienmia
BTK Inhibitor
Chemoimmunotherapy
Clinical trials

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Recent advances in the understanding of Waldenström macroglobulinemia (WM) biology have impacted the development of effective novel agents and improved our knowledge of how the genomic background of WM may influence selection ...
Lire la suite >Recent advances in the understanding of Waldenström macroglobulinemia (WM) biology have impacted the development of effective novel agents and improved our knowledge of how the genomic background of WM may influence selection of therapy. Consensus Panel 7 (CP7) of the 11th International Workshop on WM was convened to examine the current generation of completed and ongoing clinical trials involving novel agents, consider updated data on WM genomics, and make recommendations on the design and prioritization of future clinical trials. CP7 considers limited duration and novel-novel agent combinations to be the priority for the next generation of clinical trials. Evaluation of MYD88, CXCR4 and TP53 at baseline in the context of clinical trials is crucial. The common chemoimmunotherapy backbones, bendamustine-rituximab (BR) and dexamethasone, rituximab and cyclophosphamide (DRC), may be considered standard-of-care for the frontline comparative studies. Key unanswered questions include the definition of frailty in WM; the importance of attaining a very good partial response or better (≥VGPR), within stipulated time frame, in determining survival outcomes; and the optimal treatment of WM populations with special needsLire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T02:06:23Z
2024-04-05T08:45:28Z